Kailera Therapeutics (NASDAQ:KLRA) Coverage Initiated by Analysts at Leerink Partners

Investment analysts at Leerink Partners started coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a report released on Tuesday. The brokerage set an “outperform” rating and a $36.00 price target on the stock. Leerink Partners’ price target points to a potential upside of 57.00% from the stock’s previous close.

KLRA has been the topic of a number of other research reports. William Blair initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. Jefferies Financial Group initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $48.00 target price on the stock. Evercore initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. TD Cowen initiated coverage on Kailera Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Wall Street Zen raised Kailera Therapeutics to a “hold” rating in a research note on Saturday, April 25th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $42.75.

Kailera Therapeutics Stock Performance

Kailera Therapeutics stock opened at $22.93 on Tuesday. Kailera Therapeutics has a fifty-two week low of $20.86 and a fifty-two week high of $28.23.

Insider Buying and Selling at Kailera Therapeutics

In other Kailera Therapeutics news, Director Andrew T. Kaplan purchased 8,398,438 shares of the business’s stock in a transaction on Monday, April 20th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $134,375,008.00. Following the completion of the transaction, the director directly owned 26,255,581 shares in the company, valued at approximately $420,089,296. This represents a 47.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Adam Koppel purchased 1,562,500 shares of the business’s stock in a transaction on Monday, April 20th. The shares were acquired at an average price of $16.00 per share, with a total value of $25,000,000.00. Following the completion of the transaction, the director owned 22,583,268 shares of the company’s stock, valued at approximately $361,332,288. This trade represents a 7.43% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 10,460,938 shares of company stock worth $167,375,008 over the last three months.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.